Indoco Remedies Shares Rally After USFDA Approval Boost

Shares of Indoco Remedies Limited closed higher on the NSE after the company secured final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Brivaracetam Oral Solution, a treatment used for partial-onset seizures in patients aged one month and above. The regulatory nod opens up significant commercial potential in the US market, one of the largest for branded and generic drugs. Investors welcomed the development, reflecting optimism over stronger future revenue streams and improved product portfolio diversification. The stock outperformed broader market weakness in the closing session as traders positioned for potential earnings growth driven by new product launches and export market expansion. This positive catalyst provided some relief after a volatile trading day dominated by sector-wide pressure, especially in information technology stocks. Disclaimer: Investments in securities are subject to market risk. This is for educational purposes only. Investors must verify information before investing and consider their financial position & risk profile.